Teprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye Disease | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!

Teprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye Disease


Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.

“These analyses provide insight into both the short-term and long-term efficacy and safety of teprotumumab and are clinically relevant as all objective signs and symptoms of thyroid eye disease, especially proptosis and diplopia, which can be resistant to medical therapy, were markedly and significantly improved with teprotumumab,” George J. Kahaly, MD, PhD, a professor of medicine, endocrinology and metabolism at Johannes Gutenberg University Medical Center in Mainz, Germany, and colleagues wrote in a study published in The Lancet Diabetes & Endocrinology.

Teprotumumab Improves Short And Long-Term Clinical Outcomes In Thyroid Eye Disease